Alexander Balck
Alexander Balck, MD
Clinician scientist
Phone number:+49 451 3101 8221

Current Position:

Research fellow at the Institute of Neurogenetics, University of Lübeck

Resident at the Department of Neurology, University of Lübeck

Research focus:

Genetics of movement disorders with a focus Parkinson’s diseases;
Identification of novel drug candidates and biomarkers a subset of Parkinson’s disease (PD) patients with overt mitochondrial dysfunction (

Education & Scientific training


10/2009 – 09/2011 Medical School at the University of Lübeck

10/2011 – 06/2016 Medical School at the Georg August University of Göttingen
08/2017 - present Neurology Resident, University Clinic of Schleswig-Holstein, Campus Lübeck
2011 - 2017 Doctoral thesis at the Department of Neurology, Georg August University of Göttingen, Topic: “Combination treatment with fasudil and riluzole in the SOD1-G93A mouse model of amyotrophic lateral sclerosis”

Scientific training:

07/2016 – 08/2017 Research fellowship at the Institute of Neurogenetics, University of Lübeck
09/2018 – present Research fellowship at the Institute of Neurogenetics, University of Lübeck
Complete list of Publications

Complete list of Publications:

1: Dulovic M, Schäffer E, Leypoldt F, Balck A, Schaake S, Hinrichs F, Kirchner H, Brüggemann N, Berg D, Lohmann K. A Klinefelter patient with an additional mitochondrial mutation: Implications for genotype-driven treatment and mitochondrial mutational load in different tissues and family members. Parkinsonism Relat Disord. 2018 Apr 3. pii: S1353-8020(18)30146-9. doi: 10.1016/j.parkreldis.2018.04.001. [Epub ahead of print] PubMed PMID: 29650490.

2: Kasten M, Hartmann C, Hampf J, Schaake S, Westenberger A, Vollstedt EJ, Balck  A, Domingo A, Vulinovic F, Dulovic M, Zorn I, Madoev H, Zehnle H, Lembeck CM, Schawe L, Reginold J, Huang J, König IR, Bertram L, Marras C, Lohmann K, Lill CM, Klein C. Genotype-Phenotype Relations for the Parkinson's Disease Genes Parkin, PINK1, DJ1: MDSGene Systematic Review. Mov Disord. 2018 May;33(5):730-741. doi: 10.1002/mds.27352. Epub 2018 Apr 11. Review. PubMed PMID: 29644727.

3: Balck A, Tunc S, Schmitz J, Hollstein R, Kaiser FJ, Brüggemann N. A Novel Frameshift CACNA1A Mutation Causing Episodic Ataxia Type 2. Cerebellum. 2018 Aug;17(4):504-506. doi: 10.1007/s12311-018-0931-8. PubMed PMID: 29497979.

4: Balck A, Hanssen H, Hellenbroich Y, Lohmann K, Münchau A. Adult-onset ataxia or developmental disorder with seizures: two sides of missense changes in CACNA1A. J Neurol. 2017 Jul;264(7):1520-1522. doi: 10.1007/s00415-017-8494-z. Epub 2017 Apr 28. PubMed PMID: 28455667.

5: Balck A, Klein C. Reduced penetrance of Leucine-rich repeat kinase 2 mutations: Discovering genetic factors of endogenous disease protection. Mov Disord. 2017 Apr;32(4):527. doi: 10.1002/mds.26940. Epub 2017 Feb 20. PubMed PMID: 28218415.

6: Günther R, Balck A, Koch JC, Nientiedt T, Sereda M, Bähr M, Lingor P, Tönges L. Rho Kinase Inhibition with Fasudil in the SOD1(G93A) Mouse Model of Amyotrophic Lateral Sclerosis-Symptomatic Treatment Potential after Disease Onset. Front Pharmacol. 2017 Jan 31;8:17. doi: 10.3389/fphar.2017.00017. eCollection 2017. PubMed PMID: 28197100; PubMed Central PMCID: PMC5281550.

7: Tönges L, Günther R, Suhr M, Jansen J, Balck A, Saal KA, Barski E, Nientied T, Götz AA, Koch JC, Mueller BK, Weishaupt JH, Sereda MW, Hanisch UK, Bähr M, Lingor P. Rho kinase inhibition modulates microglia activation and improves survival in  a model of amyotrophic lateral sclerosis. Glia. 2014 Feb;62(2):217-32. doi: 10.1002/glia.22601. Epub 2013 Dec 6. PubMed PMID: 24311453.


< Go back